Sonus Pharmaceuticals Inc (Other) (8-K)
24 Septiembre 2007 - 12:41PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported)
September 24, 2007
SONUS
PHARMACEUTICALS, INC.
(Exact name of
Registrant as Specified in Its Charter)
Delaware
|
|
0-26866
|
|
95-4343413
|
(State or other
jurisdiction
|
|
(Commission
|
|
(IRS Employer
|
of
incorporation)
|
|
File Number)
|
|
Identification
No)
|
22026 20
th
Avenue S.E., Bothell, Washington 98021
(Address of
principal executive offices)
(425)
487-9500
(Registrants
telephone number, including area code)
Not
Applicable
(Former name or
former address, if changed since last report)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the filing
obligation of the registrant under any of the following provisions:
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to
Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
8.01 Other Events.
The Company issued a
press release on September 24, 2007 announcing the results of its Phase 3 trial
for TOCOSOL Paclitaxel. The press
release is attached as Exhibit 99.1 hereto.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit 99.1 Press release issued by Sonus
Pharmaceuticals, Inc. on September 24, 2007.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
|
SONUS PHARMACEUTICALS, INC.
|
|
|
|
Date: September 24, 2007
|
By:
|
/s/ Alan Fuhrman
|
|
|
Alan Fuhrman
|
|
|
Senior Vice President and Chief Financial Officer
|
Exhibit Index
Exhibit No.
|
|
Description
|
99.1
|
|
Press release issued by Sonus Pharmaceuticals, Inc.
on September 24, 2007.
|
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Sonus (NASDAQ:SNUS)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about Sonus Pharmaceuticals (MM) (NASDAQ): 0 recent articles
Más de Sonus Pharmaceuticals Inc Artículos de Noticias